ArticleMicroorganisms2026
Novel Thermostabilizing Formulation for Enhanced Stability of Foot-and-Mouth Disease Virus During Storage and Environmental Stress.
Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Among the seven-foot-and-mouth disease virus (FMDV) serotypes, serotype O is relatively thermolabile, posing significant challenges for virus preservation and vaccine manufacturing. Therefore, this study aimed to develop an effective thermostabilizing formulation to enhance the thermal stability of thermolabile FMDV serotype O strains, thereby facilitating their long-term storage. The stabilizing effect of a newly developed stabilizer, designated CVS, was assessed using two Korean field isolates (O/SKR/Jincheon/2014 and O/SKR/Boeun/2017) and two recombinant strains [O1 Manisa (R) and O PanAsia-2 (R)]. CVS was compared with conventional stabilizers consisting of 3% sucrose and 10% glycerol. Viral seed stocks were stored at -80 °C, 4 °C, 25 °C and 37 °C for 2, 4, and 7 d or subjected to accelerated stress conditions, after which viral thermostability was comparatively evaluated. Although 3% sucrose provided moderate protection, the CVS formulation demonstrated significantly superior stabilizing efficacy on viral infectivity, particularly under high-temperature stress conditions (25 °C and 37 °C) and during freeze-thaw cycles. However, the stabilizing effect varied among strains, suggesting strain-dependent differences in physicochemical properties and structural stability. Overall, CVS improved FMDV infectivity stability across a broad temperature range and exhibited greater protective efficacy than 3% sucrose, supporting its potential as an effective FMDV stabilizer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.